Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: COVID-19
Phase 2: Communicable Diseases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
WPV01-CP-23 | P3 |
Completed |
COVID-19 |
2023-08-21 |
|
WPV01-CP-02 | P2 |
Completed |
COVID-19|Communicable Diseases |
2023-05-09 |
|
WPV01-CP-01 | P1 |
Completed |
Healthy Volunteers |
2023-03-11 |